Realheart has patent protection of the general pump principle in the United States, the U.K., Sweden and Germany.
A new patent was granted for Sweden, UK and China in order to protect the latest version of Realheart TAH. This is also submitted for the United States, Japan, Australia, Canada and India. These markets are the largest and most important markets for artificial hearts as of now, except for China and India which are considered to be important emerging markets.
Apart from the patent protection as described above, Realheart’s patent portfolio also covers future products in the R&D pipeline: Sternal prosthesis, PulsePump, and RealVAD, Realheart PulsePump and Realheart Sternal prosthetic. During 2018, a new connective socket for a simple and safe connection between Realheart TAH and the body’s circulatory system was designed and a patent application for this has also been submitted.
The existing patents together with the new patent applications lead the board to conclude that the company has a strong patent situation and a strong protection.
Besides above is Realheart examining the possibility to license the technique to other companies.